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INTRODUCTION 
Poorly water-soluble drugs often require high doses in 
order to reach therapeutic plasma concentrations after oral 
administration. Improvement in the extent and rate of 
dissolution is highly desirable for such compounds, as this 
can lead to an increased and more reproducible oral 
bioavailability and subsequently to clinically relevant dose 
reduction and more reliable therapy. Numerous works 
have been carried out in order to modify the dissolution 
kinetics of poorly soluble drugs to improve their 
bioavailability
1
. Experience with solid dispersions over the 
last 20-30 years indicates that this is a very fruit ful 
approach to improving the solubility, dissolution rates and 
consequently the bioavailability of poorly soluble drugs
2
. 
A number of insoluble drugs has shown to improve their 
dissolution character when converted to solid dispersion. 
Solid dispersion is used to produce a homogeneous 
distribution of a small amount of drug in solid state
3
.  
The concept of SDs was introduced in 1961 by Sekiguchi 
and Obi
4
 in which the drug is dispersed in inert water 
soluble carrier at solid state. Solid dispersion technology is 
a well known process used to increase the dissolution 
kinetics and oral absorption of poorly water soluble drugs 
using water soluble inert carriers
5
. The use of hydrophilic 
polymers as carriers for the dissolution enhancement of 
poorly water-soluble drug is increasing
6
. Several water 
soluble carriers such as mannitol, urea, lactose, citric acid, 
polyvinyl pyrrolidone (PVP) and polyethylene glycols 
(PEG) are used as carriers for SDs
7
. 
Domperidone is described chemically  as 5-ch loro-1-[1-[3-
(2, 3-dihydro-2-oxo-1H-benzimidazole-1-y l) propyl] – 4 –  
piperidiny l ] -1, 3 – dihydro - 2H - benzimidazo le -2-one8. 
The drug is a benzimidazole derivative with a molecu lar 
weight of 426. According to biopharmaceutical 
classification system (BCS), domperidone is classified  
under class-II (poor solubility and high permeability). It  
acts as an antiemetic and a prokinetic agent through its 
effects on the chemoreceptor trigger zone and motor 
function of the stomach and small intestine. Unlike 
metoclopramide, it does not cause any adverse 
neurological symptoms as it has min imal penetration 
through the blood-brain barrier. It thus provides an 
excellent safety profile for long-term admin istration orally  
in the recommended doses
9
. 
When given as immediate release tablet onset of action is 
half an hour and the drug effect lasts for 4-7h. The 
elimination half life is 5-7 hr and protein binding of 
Domperidone is 91- 93%. Although, Domperidone is a 
weak base with good solubility in acidic pH but in alkaline 
pH, its solubility is significantly reduced
10
. It has poor 
aqueous solubility (0.986mg/L) and the oral bioavailability 
of Domperidone has been reported at the range of 13-17%. 
The poor aqueous solubility may be one possible reason 
for its low bioavailability. In order to increase the 
bioavailability of domperidone, a controlled release dosage 
form has been prepared to increase the solubility of 
Domperidone in the alkaline medium
9
. 
Present study was designed to study the effect of PEG 
4000 and PVP K25 as a water soluble carrier on solubility 
and dissolution rate of domperidone. Effect of drug to 
carrier rat ios on the dissolution of domperidone was also 
studied. Solid Dispersion was prepared by co grinding and 
kneading method to compare rates of release of drug. The 
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Solid Dispersions seems to possess great potential to 
significantly enhance the solubility and dissolution rate of 
domperidone. 
MATERIAL AND METHODS 
Domperidone was received as gift sample from Cotec 
Pharma (Roorkee, India). PEG 4000 was procured from 
Titan Biotech Ltd., Bhiwadi and PVP K25, Lactose, Starch 
was procured from CDH, New Delhi. Distilled water was 
used throughout the study and all the other chemicals used 
were of analytical grade. 
PREPARATION OF SOLID DISPERS IONS OF 
DOMPERIDONE 
Solid dispersions were prepared with two carriers i.e. PEG 
4000 and PVP K25 by two different methods i.e. 
cogrinding and kneading method. 
Cogrinding method: The cogrinding mixtures of 
Domperidone were prepared using PEG 4000 and PVP 
K25 as carriers in combination in various weight ratios in a 
mortar and pestle and cogrinded for 5 minutes. The dry 
mass was pulverized by passing through sieve no. 60. The 
dried mass was stored in dessicator until fu rther use. 
Kneading method: A mixture of Domperidone, PEG 
4000 and PVP K25 in different ratios were wetted with 
water-ethanol (1:1) mixture and kneaded thoroughly for 30 
minutes in a glass mortar. The paste formed was dried in 
an oven at 40°C until dry. Dried powder was scrapped, 
crushed, pulverized and passed through sieve no 60 and 
stored in dessicator. 
Table 1: Formulation of solid d ispersions of Domperidone 
Formulation Code Domperidone (mg) PEG 4000 (mg) PVP K 25 (mg) Method  
F1  10 20 10 Cogrinding  
F2 10 20 20 Cogrinding  
F3 10 20 30 Cogrinding  
S1 10 20 10 Kneading 
S2 10 20 20 Kneading 
S3 10 20 30 Kneading 
  
Determination of percent yield
11
  
The percent yield of domperidone solid dispersions can be 
determined by using the following expression:  
Percent yield  = (weight of p repared solid dispersion / 
weight of drug + carriers) x 100 
Preparation of Domperidone solid dis persion tablets  
The required quantities of domperidone solid dispersion, 
lactose (qs), talc (1%) and magnesium stearate (1%) were 
mixed thoroughly in a dry mortar. The dried mass was 
passed through mesh no.60 to break the aggregates. The 
blend was compressed into 100 mg tablets on a rotary 
tablet punching machine with punch size of using 9 mm 
round and flat punches by direct compression as per the 
formula given in Tab le 2. 
Evaluation of Tablets: All the tablets prepared were 
evaluated for content of active ingredient, hardness, 
friability, disintegration time, d issolution rate as per 
official (I.P) methods. Hardness of tablets was tested using 
Monsanto hardness tester. Friability of the tablets was 
determined in a Roche friabilator. Disintegration time was 
determined in a tablet disintegration test machine using 
900ml 0.1M HCL as the dissolution media
12
. 
Drug Content Es timation 
Drug content was determined by weighing randomly  
selected tablets, pulverizing to a fine powder. The powder 
equivalent to 10 mg domperidone was weighed and 
dissolved in 10 ml of methanol in volumetric flask using 
magnetic stirrer, the volume was adjusted to 100 ml with 
0.1M Hcl and the solution was filtered. An aliquot of 1.0 
ml of solution were diluted to 10 ml 0.1M Hcl in separate 
volumetric flask. The drug content in was determined 
spectrophotometrically at 284 nm (λ max)13. 
 
Table 2: Preparat ion of tablets of Solid dispersion  
Ingredients F1(mg) F2(mg) F3(mg) S1(mg) S2(mg) S3(mg) 
Solid dis persion (containing 10mg of 
domperidone) 
40 50 60 40 50 60 
Lactose 33 23 13 33 23 13 
Starch 25 25 25 25 25 25 
Magnesium stearate 1 1 1 1 1 1 
Talc 1 1 1 1 1 1 
Total weight 100mg  100mg 100mg 100mg  100mg 100mg 
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Fourier-transform infrared (FTIR) s pectroscopy 
Fourier-transform infrared (FT-IR) spectra were recorded 
using an FT-IR spectrophotometer (Sh imadzu). The 
samples (domperidone  and its SDs) were previously 
ground and mixed thoroughly with potassium bromide, an  
infrared transparent matrix, at 1:5 (Sample: KBr) ratio, 
respectively. The KBr discs were prepared by compressing 
the powders at a pressure of 5 tons for 5 min in a hydraulic 
press. The scanning range was 400-4700 cm-1
14
. 
Differential scanning calorimetry (DSC) 
A differential scanning calorimeter (DSC 7, PERKIN-
ELMER) at IIT Delhi was used to obtain the DSC curves 
representing the rates of heat uptake. About 5 mg of 
sample was weighed in a standard open aluminum pan. An 
empty pan of the same type was used as the reference. 
Samples were heated from 50 to 300 °C at a heating rate of 
10 °C/min while being purged with dry n itrogen. 
Calibrat ions of temperature and heat flow were performed  
with indium
15
. 
Dissolution studies: 
Dissolution studies were conducted using USP II paddle 
type dissolution apparatus by taking an accurately weighed 
amount of the prepared system equivalent to 10 mg of the 
drug was added to each jar. The d issolution medium used 
was 900 ml of 0.1N HCl, maintained at 37±0.5 °C  at a  
speed of 50 rpm. The dissolution study was performed for 
1 hr. 5 ml sample was withdrawn out at specified intervals 
of time and filtered. The in itial volume was maintained by 
adding 5 ml of fresh dissolution medium to maintain a 
constant volume after each sampling. The removed 
samples were analyzed spectrophotometrically at 284.0 nm 
(λmax). Similarly a comparative in vit ro drug release 
evaluation was also carried out between the prepared 
systems F1, F2, F3, S1, S2, S3 and a marketed formulat ion 
(tablet). 
RES ULTS AND DISCUSS ION 
Percentage Yield:  
The percent yield of domperidone solid dispersions ranged 
between 97 to 99%.  
Drug content: Results depicted in Table 3 shows that the 
drug concentration in solid dispersions ranged between 
97.86 and 98.96 %. 
 
Table 3: % Drug content in Solid d ispersion Formulations 
Formulation code  F1  F2  F3  S1 S2 S3 
%  Drug Content 97.86 98.91 98.85 98.2 98.96 97.93 
  
Evaluation of prepared tablets 
Hardness, disintegration time and friability of all 
formulat ions were found between 4 to 6 kg/cm2, 2.3 to 6.5 
min and 0.30 to 0. 47 %. Release profile of all the 
formulat ion was shown in Figure 1. It was found that 
Batch S2 gives desirable fast release action. Moreover, 
hardness, disintegration time, and friability of  S2 tablet 
were found 4±0.2 kg/cm2 , 2.3min and 0.31 %.  
Dissolution Studies  
Dissolution profiles of prepared solid dispersion tablets 
and marketed samples in different media were studied is 
shown in figure 1, 2 and 3. It is evident that the solid 
dispersion technique has improved the dissolution rate of 
domperidone to a great extent. The figure indicated that 
the formulat ion (S2) 1:2:2 of DOM:PEG:PVP gives  fast 
dissolution rate 85.77% of drug in 0.1M Hcl media as 
compared to formulation (F2) gives dissolution rate  
83.80% of drug  and marketed product (MP)  dissolution 
rate 81.01% in one hour (Table 4). In pH 4.5 Acetate 
media, the percentage of drug release in one hour were 
(S2) 72.39% , (F2) 69.44.14% and(MP) 67.47% (Table 5). 
In pH 6.8 Phosphate media, the percentage of drug release 
in one hour were (S2) 64.63%, (F2 ) 62.24% and(MP) 
60.25% (Table 6). The enhancement of dissolution of 
domperidone from the drug carrier may be due to several 
factors such as lack of crystallinity, increased wettability 
and dispersibility. Incorporation of drug with a hydrophilic 
carrier system offered an increased wetting and reduction 
in interfacial tension between hydrophobic drug and 
dissolution medium. The order of efficiencies of products 
based on percentage drug release after 60 minutes is 
S2>F2>marketed formulat ion>S1>F1>S3>F3.  
 
Table 4: % Drug release in 0.1M HCL buffer 
 Time(min) Market product (MP) F1  F2  F3  S1 S2 S3 
5 51.01     47.57 52.16 45.27 48.88 55.27 46.75 
10 52.00 49.70 53.80 46.91 50.52 57.57 49.04 
15 55.44 51.67 58.39 49.04 53.47 60.19 51.01 
30 73.96 69.37 75.60 66.91 71.34 77.90 67.73 
60 81.01 76.26 83.80 72.81 78.39 85.77 75.60 
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Table 5: % Drug release in pH 4.5 Acetate buffer 
Time (min) Market product (MP) F1  F2  F3  S1 S2 S3 
5 40.09     36.49 41.40             32.88 38.29 43.70 35.18 
10 41.73 37.96 42.88 34.52 40.26 45.50 36.98 
15 43.86 40.09 45.01 36.32 42.72 48.45 38.13 
30 57.63 53.37 60.09 49.11 55.67 63.21 52.06 
60 67.47 63.21 69.44 58.95 65.50 72.39 61.40 
 
Table 6: % Drug release in pH 6.8 Phosphate buffer 
Time(min) Market product (MP) F1  F2  F3  S1 S2 S3 
5 18.03 16.44 20.82 13.65 17.24 23.61 15.25 
10 21.22 18.43 22.42 15.65 19.23 26.80 17.24 
15 24.41 20.03 26.80 18.03 22.81 29.58 19.63 
30 45.51 40.73 47.11 35.96 43.12 50.29 38.74 
60 60.25 55.47 62.24 50.29 57.06 64.63 53.08 
 
 
Figure 1: Comparative dissolution profiles of domperidone solid 
dispersion and marketed product (MP) in 0.1M Hcl buffer 
 
Figure 2: Comparative dissolution profiles of domperidone solid 
dispersion and marketed product (MP) in pH 4.5 Acetate buffer  
Differential scanning calorimetry (DSC) 
The DSC curves of pure domperidone and its solid 
dispersion using PEG 4000 and PVP K 25 comb ination 
(S2) are shown in Fig. 7. The DSC curves of pure 
domperidone showed one sharp endothermic peak at  
251.482°C corresponding to domperidone crystalline 
nature with enthalpy (ΔH) of 105.605 J/g. On the other 
hand, the DSC curves of domperidone solid dispersion 
using PEG 6000 and PVP K 30 combination showed two 
endothermic peaks, a sharp peak at 59.742°C 
corresponding to PEG with enthalpy (ΔH) of 70.472 J/g 
and a broad peak at 212.580°C corresponding to 
domperidone in solid dispersion with enthalpy (ΔH) of 
51.194 J/g. Peak temperature in solid dispersions shifted 
slightly to lower temperature with respect to the drug alone 
and there was a decrease in ΔH value of solid 
dispersion(51.194 J/g ) compared to the pure drug 
(105.605 J/g). These phenomena could be attributed to the 
amorphous form of the drug in solid dispersions and 
indicating absence of crystalline drug. 
Figure 3: Comparative dissolution profiles of domperidone solid 
dispersion and marketed product (MP)  in pH 6.8 Phosphate 
buffer 
Fourier transforms infrared (FTIR) s pectroscopy  
Fourier transform infrared spectroscopy was performed on 
pure domperidone (DMP) and its solid dispersion. Pure 
DMP spectra showed sharp characteristic peaks at 
3360,1720,2818,1677 and1488 cm-1. All the above 
characteristic peaks appear in the spectra of domperidone 
solid dispersion at same wave number indicating no 
modification or interaction between the drug and carrier.
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Figure 4: FTIR spectra of pure drug (Domperidone) 
 
        Figure 5: FTIR spectra of Domperidone + PEG 4000 + PVP K25  (1:2:2) 
 
Figure 6: FTIR spectra of Domperidone + PEG 4000 + PVP K25  (1:2:1) 
Reena et al                                   Journal of Drug Delivery & Therapeutics; 2012, 2(4), 152-158    157 
© 2011, JDDT. All Rights Reserved                                                          ISSN: 2250-1177                                                   CODEN (USA): JDDTAO 
 
 
 
Figure 7: DSC curve of pure domperidone 
 
 
Figure 8: DSC curve of domperidone + PEG 4000 + PVP K25 (1:2:1) 
DISCUSS ION 
The enhancement of dissolution of domperidone from drug 
carrier systems can be described to several other factors 
also. Lack of crystallinity, i.e. amorphization, increased 
wettability, dispersibility and particle size reduction  are 
considered to be important factors for dissolution rate 
enhancement. As indicative from dissolution data of 
cogrinding mixtures, improvement could be attributed to 
higher wettability and dispersibility. Dry mixing of drug 
with a hydrophilic carrier results in greater wetting and 
increases surface available for dissolution by reducing 
interfacial tension between hydrophobic drug and 
dissolution media. Furthermore, kneading results in 
uniform distribution of drug in the polymer crust in a 
highly dispersed state. Thus, when such a system comes  in 
contact with an aqueous dissolution medium, the 
hydrophilic carrier dissolves and results in precipitation of 
the embedded drug into fine particles, which increase the 
dissolution surface available. Moreover, other factors such 
as absence of aggregation and/or reagglomerat ion 
phenomenon during dissolution and particle size reduction 
could be attributed to a better dissolution profile.   
CONCLUS ION  
Domperidone is practically insoluble in water and aqueous 
flu ids. As such the oral absorption of domperidone is 
dissolution rate limited. Among the various approaches to 
improve the dissolution of poorly soluble drugs, the 
preparation of solid dispersions has often proven to be very 
successful; hydrophilic carrier was used in the preparation 
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of solid dispersions and evaluated for their efficiency in 
increasing the dissolution rate of domperidone. So lid  
dispersions of domperidone in PEG and PVP were 
prepared as cogrinding mixture and by kneading method. 
The study shows that the dissolution rate of domperidone 
may be enhanced to a great extent by solid dispersion 
technique using kneading method. 
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